Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

81.62 +5.87 (+7.75%)
Streaming Delayed Price Updated: 12:03 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,298
Open 78.36
Bid (Size) 80.45 (100)
Ask (Size) 82.45 (100)
Prev. Close 75.75
Today's Range 76.00 - 82.35
52wk Range 11.17 - 83.00
Shares Outstanding 98,935,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
From Palvella Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+580.2%
+580.2%
1 Month
+20.1%
+20.1%
3 Month
+108.9%
+108.9%
6 Month
+269.8%
+269.8%
1 Year
+536.2%
+536.2%

More News

Read More
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For August 14, 2025
Via Benzinga
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Wider Q2 2025 Loss, Stock Drops 13% Despite Clinical Progress
Via Chartmill
Palvella Posts Cash Gain and Trial Wins
Via The Motley Fool
Topics Intellectual Property
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For May 15, 2025
Via Benzinga

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
What is the current price of Palvella Therapeutics, Inc. - Common Stock?
The current price of Palvella Therapeutics, Inc. - Common Stock is 81.62
When was Palvella Therapeutics, Inc. - Common Stock last traded?
The last trade of Palvella Therapeutics, Inc. - Common Stock was at 11/06/25 12:03 PM ET
What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 8.08B
How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
Palvella Therapeutics, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.